Evidence map›Paper›PMID 35184752›Full record

ReviewTranslational neurodegeneration2022

Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Philipp Mahlknecht, Kathrin Marini, Mario Werkmann, Werner Poewe, Klaus Seppi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Philipp MahlknechtDepartment of Neurology, Innsbruck Medical University, 6020, Innsbruck, Austria.ORCID 0000-0003-0671-0516
Kathrin MariniDepartment of Neurology, Innsbruck Medical University, 6020, Innsbruck, Austria.
Mario WerkmannDepartment of Neurology, Innsbruck Medical University, 6020, Innsbruck, Austria.
Werner PoeweDepartment of Neurology, Innsbruck Medical University, 6020, Innsbruck, Austria. Werner.Poewe@i-med.ac.at.
Klaus SeppiDepartment of Neurology, Innsbruck Medical University, 6020, Innsbruck, Austria. Klaus.Seppi@tirol-kliniken.at.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ultimate goal in Parkinson's disease (PD) research remains the identification of treatments that are capable of slowing or even halting the progression of the disease. The failure of numerous past disease-modification trials in PD has been attributed to a variety of factors related not only to choosing wrong interventions, but also to using inadequate trial designs and target populations. In patients with clinically established PD, neuronal pathology may already have advanced too far to be modified by any intervention. Based on such reasoning, individuals in yet prediagnostic or prodromal disease stages, may provide a window of opportunity to test disease-modifying strategies. There is now sufficient evidence from prospective studies to define diagnostic criteria for prodromal PD and several approaches have been studied in observational cohorts. These include the use of PD-risk algorithms derived from multiple established risk factors for disease as well as follow-up of cohorts with single defined prodromal markers like hyposmia, rapid eye movement sleep behavior disorders, or PD gene carriers. In this review, we discuss recruitment strategies for disease-modification trials in various prodromal PD cohorts, as well as potential trial designs, required trial durations, and estimated sample sizes. We offer a concluding outlook on how the goal of implementing disease-modification trials in prodromal cohorts might be achieved in the future.

Indexed as

Parkinson DiseaseREM Sleep Behavior DisorderBiomarkersHumansProdromal SymptomsProspective StudiesBiomarkersEpidemiologyNeuroprotectionNeuroprotectivePreclinicalPreventionPreventiveProbabilityRandomized controlled trial

Identifiers

PMID35184752
PMCPMC8859908
OpenAlexW4213255175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.